

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

[pLKO.1 puro](#)

RRID:Addgene_8453

Type: Plasmid

Proper Citation

RRID:Addgene_8453

Plasmid Information

URL: <http://www.addgene.org/8453>

Proper Citation: RRID:Addgene_8453

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:12649500](#)

Vector Backbone Description: Backbone Size:7032; Vector Backbone:pLKO.1; Vector Types:Mammalian Expression, Lentiviral, RNAi; Bacterial Resistance:Ampicillin

Comments: Empty lentiviral vector for siRNA expression; replaces Lentihair; see author's map. The 293T cell line can be obtained from the Weinberg lab or GenHunter <http://genhunter.com/products/aptag-3/index.html> Note that Addgene's quality control sequence shows that there are about 25 nucleotides between the AgeI and EcoRI sites (the depositor sequences is not as accurate in this region). For packaging, please use pCMV-dR8.2 dvpr (Addgene plasmid #8455) and pCMV-VSVG (Addgene plasmid #8454). For the official vector of The RNAi Consortium and a plasmid map, please see plasmid #10878.

Plasmid Name: pLKO.1 puro

Record Creation Time: 20220422T222545+0000

Record Last Update: 20260905T080231+0000

Ratings and Alerts

No rating or validation information has been found for pLKO.1 puro.

No alerts have been found for pLKO.1 puro.

Data and Source Information

Usage and Citation Metrics

We found 744 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Criscuolo D, et al. (2026) CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC. Cancer research communications, 6(1), 201.

Metcalf SA, et al. (2026) Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions. FEBS letters, 600(8), 1248.

Huo Y, et al. (2026) FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity. Cancer research, 86(9), 2184.

Jin W, et al. (2026) Epithelial Gab1 Restricts Sepsis-Induced Intestinal Injury by Orchestrating TNF/NF- κ B Axis. Mediators of inflammation, 2026, 5486971.

Kim JK, et al. (2026) Loss of ABCA3 disrupts lipid balance and leads to AMPK-dependent suppression of SREBP1 in glioblastoma stem cells. Oncogene, 45(15), 1357.

Citron F, et al. (2026) DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Cancer research, 86(12), 2837.

Tong B, et al. (2026) A nature-inspired nanoplatform for multi-protein targeted degradation via the autophagy-lysosome pathway. Cell chemical biology, 33(4), 523.

Yin K, et al. (2026) Claudin-1 Interacts with CD81 and Promotes the Progression of Colorectal Cancer. Oncology research, 34(6), 30.

Mi W, et al. (2026) LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. Cell reports, 45(6), 117487.

Bai L, et al. (2026) AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling. Cell reports, 45(6), 117394.

Wang M, et al. (2026) ELF3 drives glioblastoma multiforme progression through the regulation of MXRA8 expression. Scientific reports, 16(1).

Aksu AM, et al. (2026) JNK1 mediates serine phosphorylation of STAT3 in response to fatty acids released by lipolysis. Journal of lipid research, 67(3), 100991.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. Cell reports, 45(2), 116970.

Tian H, et al. (2026) SDF2L1 modulates oxLDL-induced endoplasmic reticulum stress, protein aggregation, and O-mannosylation in myocardial infarction and lung cancer.

Cellular and molecular life sciences : CMLS, 83(1).

Wang Z, et al. (2026) Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins. *Journal of medicinal chemistry*, 69(7), 8417.

Bergman M, et al. (2026) A dual role for cGAS in shaping cellular and organismal responses to genomic instability. *Genes & development*, 40(11-12), 852.

Tang J, et al. (2026) ?1,4-galactosyltransferase III drives retinoblastoma invasion via activation of integrin-FAK axis. *Cell death & disease*, 17(1).

Song X, et al. (2026) AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of *Acorus tatarinowii* in glioblastoma. *Frontiers in pharmacology*, 17, 1811032.

He Y, et al. (2026) SHCBP1 Is Upregulated in Colon Adenocarcinoma and Promotes Tumor Cell Proliferation and Growth. *Current oncology (Toronto, Ont.)*, 33(5).

Guo Q, et al. (2026) Inducible T Cell Costimulator Ligand and Inducible T Cell Costimulator Stratification Identify Dichotomous Tumor Microenvironment and Guide Chemo-Immunotherapy in Small Cell Lung Cancer. *MedComm*, 7(6), e70782.